Research Analysts Set Expectations for NKTR Q1 Earnings

Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Investment analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Nektar Therapeutics in a research note issued to investors on Tuesday, June 24th. HC Wainwright analyst A. He expects that the biopharmaceutical company will post earnings per share of ($3.00) for the quarter. HC Wainwright currently has a "Buy" rating and a $120.00 price target on the stock. The consensus estimate for Nektar Therapeutics' current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Nektar Therapeutics' Q3 2026 earnings at ($3.06) EPS.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($3.30) earnings per share for the quarter, missing analysts' consensus estimates of ($2.70) by ($0.60). Nektar Therapeutics had a negative net margin of 152.49% and a negative return on equity of 329.54%. The company had revenue of $10.46 million for the quarter, compared to analyst estimates of $15.61 million. During the same quarter in the prior year, the business earned ($2.70) earnings per share.

A number of other research firms have also recently commented on NKTR. Wall Street Zen cut Nektar Therapeutics from a "hold" rating to a "sell" rating in a research note on Wednesday, May 14th. William Blair reissued a "market perform" rating on shares of Nektar Therapeutics in a research note on Monday, May 12th. Oppenheimer upgraded Nektar Therapeutics from a "market perform" rating to an "outperform" rating and set a $90.00 target price for the company in a report on Friday, March 14th. Jefferies Financial Group upgraded shares of Nektar Therapeutics from a "hold" rating to a "buy" rating and boosted their price target for the stock from $15.00 to $30.00 in a research note on Friday, April 11th. Finally, BTIG Research increased their price target on shares of Nektar Therapeutics from $60.00 to $100.00 and gave the stock a "buy" rating in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $76.43.

Nektar Therapeutics Stock Performance

NASDAQ:NKTR opened at $29.12 on Thursday. Nektar Therapeutics has a fifty-two week low of $6.48 and a fifty-two week high of $37.38. The company has a 50 day moving average price of $10.79 and a 200 day moving average price of $12.05. The stock has a market capitalization of $361.38 million, a P/E ratio of -3.03 and a beta of 0.55.

Institutional Investors Weigh In On Nektar Therapeutics

Hedge funds have recently bought and sold shares of the stock. Two Sigma Securities LLC increased its stake in shares of Nektar Therapeutics by 56.3% during the fourth quarter. Two Sigma Securities LLC now owns 27,654 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 9,958 shares during the period. Harvest Investment Services LLC purchased a new stake in shares of Nektar Therapeutics in the 4th quarter valued at approximately $27,000. US Asset Management LLC acquired a new stake in shares of Nektar Therapeutics in the 4th quarter valued at $31,000. Algert Global LLC acquired a new stake in shares of Nektar Therapeutics in the 1st quarter valued at $33,000. Finally, US Bancorp DE lifted its position in shares of Nektar Therapeutics by 257.8% during the 1st quarter. US Bancorp DE now owns 50,085 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 36,085 shares during the last quarter. Institutional investors and hedge funds own 75.88% of the company's stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.